Abstract:
The present invention provides attenuated M. haemolitica strains that elicit an immune response in animal against M. haemolitica, compositions comprising said strains, methods of vaccination against M. haemolitica, and kits for use with such methods and compositions. The invention further provides multi-valent vaccines, which provide protective immunity when administered in an effective amount to animals susceptible to “shipping fever” or bovine respiratory disease.
Abstract:
Provided are 1-aryl-5-alkyl pyrazole compounds, of formula (I): wherein: R1 is hydrogen, cyano, halogen, R8, formyl, —C(O)R8, —C(O)OR8, —C(O)NR9R10, or —C(S)NH2; R2 is R8 or —S(O)mR11; R3 is methyl, ethyl or C1-C4 haloalkyl; R4, R5 and R7 are independently hydrogen, halogen, alkyl, haloalkyl, cyano or nitro; R6 is halogen, alkyl, haloalkyl, alkoxy, haloalkyloxy, cyano, nitro, —C(O)R12, —S(O)nR12 or SF5; Z is a nitrogen atom or C—R13; R8 is alkyl, haloalkyl, cycloalkyl or halocycloalkyl; R9 is hydrogen, alkyl, haloalkyl or alkoxy; R10 is hydrogen, alkyl, haloalkyl or alkoxy; R11 is alkyl, haloalkyl, alkenyl, haloalkenyl, alkynyl, haloalkynyl or cycloalkyl; R12 is alkyl or haloalkyl; R13 is hydrogen, halogen, cyano, nitro, alkyl, haloalkyl, alkoxy or haloalkoxy; m is 0, 1 or 2; and n is 0, 1 or 2; or a salt thereof, the method of making compounds of formula (I) and the use of these compounds against ectoparasites, endoparasites and pests.
Abstract translation:提供式(I)的1-芳基-5-烷基吡唑化合物:其中:R 1是氢,氰基,卤素,R 8,甲酰基,-C(O)R 8,-C(O)OR 8,-C )NR 9 R 10或-C(S)NH 2; R2是R8或-S(O)mR11; R3是甲基,乙基或C1-C4卤代烷基; R4,R5和R7独立地是氢,卤素,烷基,卤代烷基,氰基或硝基; R 6是卤素,烷基,卤代烷基,烷氧基,卤代烷氧基,氰基,硝基,-C(O)R 12,-S(O)n R 12或SF 5; Z是氮原子或C-R13; R8是烷基,卤代烷基,环烷基或卤代环烷基; R9是氢,烷基,卤代烷基或烷氧基; R 10是氢,烷基,卤代烷基或烷氧基; R11是烷基,卤代烷基,烯基,卤代烯基,炔基,卤代炔基或环烷基; R12是烷基或卤代烷基; R 13是氢,卤素,氰基,硝基,烷基,卤代烷基,烷氧基或卤代烷氧基; m为0,1或2; 且n为0,1或2; 或其盐,制备式(I)化合物的方法以及这些化合物对外寄生虫,内寄生虫和害虫的用途。
Abstract:
This disclosure provides attenuated swine influenza strains, particularly those produced via a reverse genetics approach, compositions comprising same, and methods of production and use thereof. The attenuated strains are engineered to encode HA proteins having additional glycosylation sites, relative to the HA proteins encoded by the corresponding virulent parental viruses. Advantageously, the attenuated influenza strains may be administered
Abstract:
The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.
Abstract:
The present invention provides compositions and methods for eliciting heterologous protective immunity in animals against Leptospira spp. The Leptospira spp. immunoprotective peptides disclosed herein elicit protective immunity against subsequent challenge or exposure to at least two Leptospira spp. serovars.
Abstract:
This invention relates to processes for the preparation of antiparasitic isoxazoline compounds enriched in an enantiomer using quinine-based chiral phase transfer catalyst. The invention also relates to novel quinine-based phase transfer catalysts and to a toluene solvent form of the isoxazoline compound of the invention.
Abstract:
The present invention relates to novel stable compressed vaccine composition composing at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.
Abstract:
A method of treating the skin or hair on a dog containing an effective amount of an ectoparasiticide previously applied to the skin or hair, comprising applying a quantity of a cleansing composition directly to the skin or hair, wherein the treatment does not result in reducing the efficacy of the ectoparasiticide against adult fleas (C. felis) or adult ticks (R. sanguineus) below 90% efficacy for at least a month after application of the ectoparasiticide; wherein the cleansing composition comprises about 1-3% glycerin; about 2-4% silicone copolyol esters, water and is essentially free of surfactant.
Abstract:
The present invention encompasses FMDV vaccines or compositions. The invention encompasses recombinant vectors encoding and expressing FMDV antigens, epitopes or immunogens which can be used to protect animals, in particular ovines, bovines, caprines, or swines, against FMDV.
Abstract:
The invention relates to a liquid applicator, for administering liquids, including vaccines, to animals. In particular, the applicator is useful for delivering liquids to mouths of animals.